BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop immuno-oncology. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naive to checkpoint inhibitors. Its other product is BXCL702.
Back to dashboard
Company Information
About this company
Key people
Peter Mueller
Lead Independent Chairman of the Board
Vimal Mehta
President, Chief Executive Officer, Director
Richard I. Steinhart
Chief Financial Officer, Senior Vice President
Frank D. Yocca
Executive Vice President, Chief Scientific Officer
Javier Rodriguez
Senior Vice President, Chief Legal Officer, Corporate Secretary
June Bray
Independent Director
Sandeep Laumas
Independent Director
David J. Mack
Independent Director
Michael Miller
Independent Director
Click to see more
Key facts
- Shares in issue31.31m
- EPICBTAIQ
- ISINUS09075P2048
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$234,790.00
- Employees29
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.